Jenburkt Pharmaceuticals Ltd.

Financial

	Jenburkt Pharma	Albert David	Ind-Swift Lab.
Operational Metrics
Pharmaceutical Sector
R&D as a % of Total Sales	0.87 %	0.54 %	3.01 %
Financials
5 yr Average ROE	18.48 %	12.32 %	9.6 %
5yr average Equity Multiplier	1.2	1.67	2.49
5yr Average Asset Turnover Ratio	0.95	0.67	0.67
5yr Avg Net Profit Margin	16.38 %	11.52 %	6.7 %
Price to Book	2.88	1.24	0.43
P/E	14.44	12.7	1.83
5yr Avg Cash Conversion Cycle	-16.2 Days	-59.38 Days	76.78 Days
Inventory Days	26.89 Days	46.72 Days	126.74 Days
Days Receivable	46.84 Days	28.39 Days	95.44 Days
Days Payable	76.62 Days	118.01 Days	94.9 Days
5yr Average Interest Coverage Ratio	75.84	90.39	3.49
5yr Avg ROCE	24.52 %	15.83 %	12.63 %
5yr Avg Operating Profit Margin	20.46 %	11.27 %	19.31 %
5 yr average Debt to Equity	0.03	0.01	1.22
5yr CAGR Net Profit	11.81 %	31.51 %	n/a
5yr Average Return on Assets	15.36 %	7.45 %	7.66 %
Shareholdings
Promoter Holding	46.68 %	62.24 %	40.94 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.95 %	0.28 %	-1.06 %
Change in Mutual Fund Holding (3 Yrs)	0.0	0.0	0.0

Business

	Jenburkt Pharma	Albert David	Ind-Swift Lab.
Product Wise Break-Up	Product Wise Break-Up Pharmaceutical 100.0 Dermatology 0	Product Wise Break-Up Pharmaceutical 0 Dermatology 0 Others 100	Product Wise Break-Up Pharmaceutical 0 Dermatology 0 Others 100
Location Wise Break-Up	Location Wise Break-Up India 85.66 Rest of the World 14.1 Others 0.24	Location Wise Break-Up India 92.79 Rest of the World 7.21	Location Wise Break-Up India 21.75 Rest of the World 0 Others 78.25